We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Test Significantly Reduces Risk of Cardiovascular Events

By LabMedica International staff writers
Posted on 30 Nov 2016
A quick, precise genetic test can significantly reduce the risk of cardiovascular events by helping to identify more effective medication for some heart patients. More...
The genetic testing allows physicians to pinpoint the best anti-clotting medication for each patient.

Decoding a patient's genetic tendencies is not just about rapid treatment as many patients take an anti-clotting drug for a year or longer. Patients who had the genetic deficiency and received an alternative medication were less likely to have a major adverse cardiovascular event compared with those who received clopidogrel during the follow-up period of up to a year.

A group of scientists led by those at the University of Florida Health (Jacksonville, FL, USA) analyzed medical outcomes in 1,815 patients who had genetic testing at the time of their cardiac procedure. The test identifies a genetic deficiency that affects the body's ability to activate clopidogrel, a common anti-clotting drug given after a coronary artery stent is inserted. The study examined the effect of genotype-guided treatment on cardiovascular outcomes after a heart procedure known as percutaneous coronary intervention, or PCI, in which a metallic stent is inserted into a heart artery to treat a blockage. More broadly, it shows the power and the promise of personalized medicine, which tailors medical decisions based on a patient's genetic information and other unique characteristics.

The study reported significant results as about 60% of patients with the genetic deficiency were given a different, more effective medication. Using the genetic data to guide changes in therapy reduced the percentage of deaths, heart attacks or strokes by nearly half compared with those who continued taking clopidogrel. Among those who had the genetic deficiency and continued taking clopidogrel, 8% of patients experienced one of those complications. About 30% of all patients have a genetic deficiency that impairs their ability to activate the drug, which can lead to decreased clopidogrel effectiveness and increased risk for adverse cardiovascular events such as strokes, heart attacks and death.

Dominick J. Angiolillo, MD, PhD, a cardiologist and professor of medicine, said, “This is an important breakthrough in personalized medicine because it shows how a genetic marker can be used to modify treatments and improve patient outcomes. There was prompt genotyping and the patients were quickly given the drug we thought would work best for them.” The study was presented at the American Heart Association's Scientific Sessions held November 12 to 16, 2016, in New Orleans. LA, USA.

Related Links:
University of Florida Health


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.